Welcome to
THABOR THERAPEUTICS
Changing the course of mucosal inflammatory diseases by blocking extracellular AGR2 to reinstate mucosal homeostasis
About Us
Thabor therapeutics is an INSERM spin off developing a first-in-class therapeutic antibody targeting AGR2 for the treatment of inflammatory mucosal diseases.
About Us
Our approach is to target the first stress signal coming from the epithelium in the context of mucosal inflammatory disorders (MIDs). Doing so, we reinstate epithelial homeostasis by preventing inflammation, fibrosis and disruption of epithelial integrity. We also bring safety to patients as our approach is not immunosuppressive.
THABOR
Collaboration Partners
Institutional & Funding Partners
